Tests depemokimab as add-on treatment for COPD with type 2 inflammation

Who can take part

• Participants must be greater than or equal to (>=) 40 to less than or equal to (<=) 80 years of age, at the time of signing the Informed consent
• Elevated Blood Eosinophil Count (BEC)
• Moderate to severe COPD with frequent exacerbations, defined as:; A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year; A post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio of < 0.70 and a post-bronchodilator FEV1 >30 percent (%) and <= 80% predicted normal values; A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening
• COPD assessment test (CAT) score >=10 at Visit 1
• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years
• Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1
• Body mass index (BMI) >=16 kilogram per square meter (kg/m\^2)
• Male and eligible female participants

Who cannot take part

• Participants with a current or prior physician diagnosis of asthma
• Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1
• Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1
• Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease
• Lung resection: Participants with a history of or plan for lung volume reduction surgery / endobronchial valve procedure
• Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension
• Unstable cardiovascular disease or arrhythmia
• Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)
• The following subjects are excluded:
• Continuous oxygen: Participants requiring oxygen supplementation for more than 16 hours per day to maintain resting oxygen saturation greater than 88%
• Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure [BiPAP] or Continuous Positive Airway Pressure [CPAP])